Administration of insulin like growth factor I (IGFI) lowers serum lipoprotein(a)-impact on atherosclerotic cardiovascular disease.

Abstract

Insulin like growth factor I (IGFI) secreted by the liver upon stimulation by pituitary growth hormone (GH) acts as the most important growth stimulating hormone in children. The present review presents evidence that among its additional metabolic effects, IGF-I suppresses the synthesis of lipoprotein(a) [Lp(a)], an independent risk factor for atherosclerotic cardiovascular disease. In view of this property, it is suggested that the addition of IGF-I to the armamentarium of hyperlipoproteinemia treatment should be considered.

• Authors: Zvi Laron, Haim Werner
• Journal: Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (Growth Horm IGF Res) Vol. 71 Pg. 101548 (08 2023) ISSN: 1532-2238 [Electronic] Scotland
• PMID: 37598644 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2023. Published by Elsevier Ltd.

Chemical References

• Growth Hormone
• Human Growth Hormone
• Insulin-Like Growth Factor I
• Lipoprotein(a)

Topics

• Child
• Humans
• Atherosclerosis
• Cardiovascular Diseases (prevention & control)
• Growth Hormone
• Human Growth Hormone
• Insulin-Like Growth Factor I (therapeutic use)
• Lipoprotein(a)